Markt geschlossen· · USD · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Revolution Medicines (RVMD) is expected to have a "strong" launch for its Rasonque drug in second-li
Equity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the commercial numbers are starting to follow. According to DelveInsight, the KRAS inhibitors market across the seven major markets was valued at approximately $526 million in 2025 and is projected to reach approximately $7.85 billion by 2034, a compound annual growth rate of roughly 35% over its 2024 to 2034 forecast period, with the United States expected
Pre-commercial precision oncology firms often face steep financial trade-offs, where absent return on invested capital/ROIC and negative operating cash flows are the price of admission for long-term clinical innovation. IDEAYA Biosciences (NASDAQ:IDYA) operates from a position of relative balance sheet strength, backed by $1.24 billion in cash, cash equivalents, and marketable securities that extend its […]
Aktuelle Schlagzeilen Dritter zu diesem Unternehmen, getrennt von Makklers eigener Redaktion und mit Verlinkung zum Herausgeber. Für die Richtigkeit ist der jeweilige Herausgeber verantwortlich.